Ypsomed founds new subsidiary
The new Group company is based in Vienna and is led by Patrick Heil, who combines this role with that of General Manager for Switzerland. Simon Michel, Head of Marketing & Sales and member of the executive management of the Ypsomed Group, explains: 'There are a number of parallels between the Austrian and Swiss markets. Based on com-parable size, close distances and additionally the common german language are allowing synergies to be exploited in customer care and management.'
Market analysis suggests that the OmniPod® tube-free insulin patch pump has considerable market potential. The other products in the mylife(TM) range are also meeting with a high level of acceptance amongst diabetics and, in par-ticular, health insurance funds. 'Our expansion into Austria supports the Ypsomed Group as it undergoes a transfor-mation and will make a long-term contribution to the Group's future profitability', adds Simon Michel. mylife(TM) commercial products will be available on the Austrian market from 1 January 2012 onwards.
The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hor-mone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. Ypsomed has established itself as a leading provider of brand, co-branding and OEM products in the retail and business-to-business segments. Ypsomed is also deeply committed to advances in patient care. Under the mylife(TM) Diabetescare brand, Ypsomed provides patients with the products it manufactures or distributes. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1,050 employees.